Population Pharmacokinetic Studies in Pediatrics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 129

Special Issue Editor


E-Mail Website
Guest Editor
Princess Máxima Center for Pediatric Oncology, Department of Pharmacology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
Interests: clinical pharmacology; pharmacogenetics; tyrosine kinase inhibitors; PK/PD/PGx studies

Special Issue Information

Dear Colleagues,

For medication use in children, there is often limited data on the pharmacokinetics and drugs with a narrow therapeutic index can cause serious side effects if dosed incorrectly (e.g. antibiotics, anticonvulsants and immunosuppressants). Information from population PK studies can be very useful in guiding dosing strategies for drugs in pediatric populations. The main challenge is that children are not small adults and they develop rapidly with many physiological changes occurring. Important developmental changes include differences in organ size, gastric pH, total body water, expression of CYP450 enzymes and glomerular filtration rate. These have an important impact on drug absorption, distribution, metabolism and excretion. Moreover, the pediatric population is subdivided into different age groups (newborn, infant, toddler, preschool child, school age child and adolescent) within which there are major differences as well. Mathematical models are used to correct for these inter-individual differences and to provide estimates on drug clearance and exposure. Additionally, Physiologically-based pharmacokinetic (PBPK) modeling incorporates detailed physiological and anatomical information about the body that allows for more personalized dosing recommendations.

This Special Issue entitled "Population Pharmacokinetic Studies in Pediatrics" presents the latest findings from popPK and PBPK studies on drugs for which safe and effective dosing in children is of great importance.

Dr. Meta H.M. Diekstra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • pediatrics
  • population PK
  • dose optimization
  • PBPK modeling

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop